MEDP · Medpace Q2 FY2026 earnings call record财报电话会记录

“Revenue for the six months ended June 30, 2026, was $1.41 billion, and increased 21.7%.”

“EBITDA margin for the second quarter was 21.7%, compared to 21.6% in the prior year period.”

“Year-to-date EBITDA margin of 21.4% was flat compared to the prior year period, as the impact of higher reimbursable costs was offset primarily by lower employee-related costs.”

“In the second quarter of 2026, net income of $121.4 million increased 34.5%, compared to net income of $90.3 million in the second quarter of 2025.”

“Ending backlog as of June 30, 2026, was approximately $3 billion, an increase of 4.9% from the prior year.”

“Regarding customer concentration, our top five and top 10 customers represent roughly 31% and 40%, respectively, of our last 12 months revenue.”

“During the second quarter, we repurchased approximately 706,000 shares for $294.7 million.”

“As of June 30, 2026, we had $527 million remaining under our share repurchase authorization program.”

“Full year 2026 total revenue is now expected in the range of $2.805 billion-$2.885 billion, representing growth of 10.9% to 14% over 2025 total revenue of $2.53 billion.”

“We forecast 2026 net income in the range of $494 million-$514 million.”

“This guidance assumes a full-year 2026 effective tax rate of 19%-19.5%, interest income of $21.1 million and no additional share repurchases assumed in our guidance.”

“The earliest part of the pipeline for awards and the backlog recognition.”